Eli Lilly and Company logo

Eli Lilly and Company (1LLY)

Market Open
4 Jul, 09:22
XMIL XMIL
659. 60
-1
-0.15%
- Market Cap
104.2 P/E Ratio
5.2% Div Yield
6 Volume
6.64 Eps
660.6
Previous Close
Day Range
659.6 663.1
Year Range
609.4 888
Want to track 1LLY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 34 days

Summary

1LLY trading today lower at €659.6, a decrease of 0.15% from yesterday's close, completing a monthly increase of 2.09% or €13.5. Over the past 12 months, 1LLY stock lost -12.64%.
1LLY pays dividends to its shareholders, with the most recent payment made on Jun 10, 2025. The next estimated payment will be in In 2 months on Sep 10, 2025 for a total of €1.5.
The last earnings report, released on Apr 28, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.08%, based on the last three reports. The next scheduled earnings report is due on Aug 07, 2025.
Eli Lilly and Company has completed 4 stock splits, with the recent split occurring on Oct 16, 1997.
The company's stock is traded on 16 different exchanges and in various currencies, with the primary listing on NYSE (USD).

1LLY Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns.

Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns.

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with Lilly and Novo.

Barrons | 6 hours ago
Wall Street Bulls Look Optimistic About Lilly (LLY): Should You Buy?

Wall Street Bulls Look Optimistic About Lilly (LLY): Should You Buy?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Zacks | 1 day ago
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock

Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Zacks | 2 days ago

Eli Lilly and Company Dividends

Eli Lilly and Company logo
LLY In 1 month
Estimated
Quarterly
$1.5 Per Share
Eli Lilly and Company logo
LLY 1 month ago
Paid
Quarterly
$1.5 Per Share
Eli Lilly and Company logo
LLY 4 months ago
Paid
Quarterly
$1.5 Per Share
Eli Lilly and Company logo
LLY 7 months ago
Paid
Quarterly
$1.3 Per Share
Eli Lilly and Company logo
LLY 10 months ago
Paid
Quarterly
$1.3 Per Share
Eli Lilly and Company logo
LLY 15 May 2024
Paid
Quarterly
$1.3 Per Share

Eli Lilly and Company Earnings

7 Aug 2025 (In 1 month) Date
5.56
Cons. EPS
-
EPS
28 Apr 2025 Date
-
Cons. EPS
-
EPS
6 Feb 2025 Date
5.07
Cons. EPS
5.32
EPS
4 Feb 2025 Date
-
Cons. EPS
-
EPS
30 Oct 2024 Date
1.47
Cons. EPS
1.18
EPS
Eli Lilly and Company logo
LLY In 1 month
Estimated
Quarterly
$1.5 Per Share
Eli Lilly and Company logo
LLY 1 month ago
Paid
Quarterly
$1.5 Per Share
Eli Lilly and Company logo
LLY 4 months ago
Paid
Quarterly
$1.5 Per Share
Eli Lilly and Company logo
LLY 7 months ago
Paid
Quarterly
$1.3 Per Share
Eli Lilly and Company logo
LLY 10 months ago
Paid
Quarterly
$1.3 Per Share
Eli Lilly and Company logo
LLY 15 May 2024
Paid
Quarterly
$1.3 Per Share
7 Aug 2025 (In 1 month) Date
5.56
Cons. EPS
-
EPS
28 Apr 2025 Date
-
Cons. EPS
-
EPS
6 Feb 2025 Date
5.07
Cons. EPS
5.32
EPS
4 Feb 2025 Date
-
Cons. EPS
-
EPS
30 Oct 2024 Date
1.47
Cons. EPS
1.18
EPS

Eli Lilly and Company (1LLY) FAQ

What is the stock price today?

The current price is €659.60.

On which exchange is it traded?

Eli Lilly and Company is listed on NYSE.

What is its stock symbol?

The ticker symbol is 1LLY.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 5.2%.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 5.56.

When is the next earnings date?

The next earnings report will release on Aug 07, 2025.

Has Eli Lilly and Company ever had a stock split?

Eli Lilly and Company had 4 splits and the recent split was on Oct 16, 1997.

Eli Lilly and Company Profile

Drug Manufacturers - General Industry
Healthcare Sector
David A. Ricks CEO
XMIL Exchange
US5324571083 ISIN
US Country
47,000 Employees
14 Feb 2025 Last Dividend
16 Oct 1997 Last Split
13 Jan 1978 IPO Date

Overview

Eli Lilly and Company is a global leader in the discovery, development, and marketing of human pharmaceuticals. With a history dating back to 1876, the company has established itself as a key player in the pharmaceutical industry, offering a wide range of products aimed at treating a variety of conditions. Headquartered in Indianapolis, Indiana, Eli Lilly and Company has forged multiple collaborations with other pharmaceutical giants such as Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., Biologics, Inc., AbCellera Biologics Inc., and Chugai Pharmaceutical Co., Ltd., enhancing its product offerings and research capabilities across different therapeutic areas.

Products and Services

  • Diabetes Care

    Includes a comprehensive portfolio of insulin and other diabetes treatments: Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500. Additionally, the company offers Jardiance, Mounjaro, and Trulicity for managing type 2 diabetes.

  • Oncology

    Provides a range of products for cancer treatment, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio, focusing on different types of cancer and treatment approaches.

  • Immunology

    Olumiant is offered for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19. Taltz is available for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.

  • Digestive Diseases

    Omvoh is targeted at ulcerative colitis, reflecting the company's commitment to addressing gastrointestinal disorders.

  • Neurological Disorders

    Includes Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is provided for migraine prevention and treatment of episodic cluster headache.

  • Other Therapeutic Areas

    The company also offers Cialis for erectile dysfunction and benign prostatic hyperplasia; Forteo for osteoporosis treatment; Zepbound for obesity management; and Ebglyss for severe atopic dermatitis, showcasing Eli Lilly's diverse portfolio catering to various health conditions.

Contact Information

Address: Lilly Corporate Center
Phone: 317 276 2000